Literature DB >> 19479193

Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy.

A Antinori1, A Ammassari, C Torti, P Marconi, M Andreoni, G Angarano, S Bonora, A Castagna, R Cauda, M Clerici, A d'Arminio Monforte, A De Luca, G Di Perri, M Galli, E Girardi, A Gori, A Lazzarin, S Lo Caputo, F Mazzotta, F Montella, C Mussini, C F Perno, M Puoti, G Rizzardini, S Rusconi, V Vullo, G Carosi.   

Abstract

BACKGROUND: Individuals with advanced HIV infection naïve to antiretroviral therapy represent a special population of patients frequently encountered in clinical practice. They are at high risk of disease progression and death, and their viroimmunologic response following the initiation of highly active antiretroviral therapy may be more incomplete or slower than that of other patients. Infection management in such patients can also be complicated by underlying conditions, comorbidities, and the need for concomitant medications. AIM: To provide practical guidelines to those clinicians providing care to HIV-infected patients in terms of diagnostic assessment, monitoring, and treatment.
CONCLUSIONS: The principals of antiretroviral treatment in asymptomatic naïve patients with advanced HIV infection are the same as those applicable to the general population with asymptomatic HIV infection. Naïve patients with advanced HIV infection and a history of AIDS-defining illnesses urgently need antiretroviral treatment, with the choice of antiretroviral regimen and timetable based on such factors as concomitant treatment and prophylaxis, drug interactions, and potential concomitant drug toxicity. Finally, an adequate counseling program - both before and after HIV-testing - that includes aspects other than treatment adherence monitoring is a crucial step in disease management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479193     DOI: 10.1007/s15010-008-8134-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  68 in total

1.  Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.

Authors:  Juan Berenguer; Juan González; Federico Pulido; Belén Padilla; José Luis Casado; Rafael Rubio; José Rarmón Arribas
Journal:  Clin Infect Dis       Date:  2001-12-19       Impact factor: 9.079

2.  Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand.

Authors:  S Sungkanuparph; W Manosuthi; S Kiertiburanakul; A Vibhagool
Journal:  J Infect       Date:  2005-06-29       Impact factor: 6.072

3.  Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Authors:  Gilbert R Kaufmann; Hansjakob Furrer; Bruno Ledergerber; Luc Perrin; Milos Opravil; Pietro Vernazza; Matthias Cavassini; Enos Bernasconi; Martin Rickenbach; Bernard Hirschel; Manuel Battegay
Journal:  Clin Infect Dis       Date:  2005-06-24       Impact factor: 9.079

4.  Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.

Authors:  A Antinori; A Cingolani; L Alba; A Ammassari; D Serraino; B C Ciancio; F Palmieri; A De Luca; L M Larocca; L Ruco; G Ippolito; R Cauda
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

5.  Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.

Authors:  Ulrik Bak Dragsted; Amanda Mocroft; Stefano Vella; Jean-Paul Viard; Ann-Britt E Hansen; George Panos; Danielle Mercey; Ladislav Machala; Andrzej Horban; Jens D Lundgren
Journal:  J Infect Dis       Date:  2004-06-09       Impact factor: 5.226

6.  Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.

Authors:  Veronica Miller; Andrew N Phillips; Bonaventura Clotet; Amanda Mocroft; Bruno Ledergerber; Ole Kirk; Vidar Ormaasen; Panagiotis Gargalianos-Kakolyris; Stefano Vella; Jens D Lundgren
Journal:  J Infect Dis       Date:  2002-07-03       Impact factor: 5.226

7.  Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.

Authors:  Andrea Antinori; Alessandro Cozzi-Lepri; Adriana Ammassari; Maria Paola Trotta; David Nauwelaers; Richard Hoetelmans; Rita Murri; Sara Melzi; Pasquale Narciso; Paola Nasta; Mauro Zaccarelli; Paola Santopadre; Jacopo Vecchiet; Crescenzo Maria Izzo; Antonella d'Arminio Maonforte
Journal:  Antivir Ther       Date:  2004-04

Review 8.  Late presentation of HIV-infected individuals.

Authors:  Manuel Battegay; Ursula Fluckiger; Bernard Hirschel; Hansjakob Furrer
Journal:  Antivir Ther       Date:  2007

9.  Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Authors:  Mathew Simcock; Monika Blasko; Urs Karrer; Barbara Bertisch; Miklos Pless; Liisa Blumer; Samir Vora; James Owen Robinson; Enos Bernasconi; Benedetta Terziroli; Sophie Moirandat-Rytz; Hansjakob Furrer; Bernard Hirschel; Pietro Vernazza; Pedram Sendi; Martin Rickenbach; Heiner C Bucher; Manuel Battegay; Michael T Koller
Journal:  Antivir Ther       Date:  2007

10.  Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.

Authors:  P Nunn; R Brindle; L Carpenter; J Odhiambo; K Wasunna; R Newnham; W Githui; S Gathua; M Omwega; K McAdam
Journal:  Am Rev Respir Dis       Date:  1992-10
View more
  2 in total

1.  Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort.

Authors:  S Leone; G Gregis; G Quinzan; D Velenti; G Cologni; L Soavi; V Ravasio; D Ripamonti; F Suter; F Maggiolo
Journal:  Infection       Date:  2011-01-19       Impact factor: 3.553

2.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.